Evaluation of Modified Vaccinia Virus Ankara as an Alternative Vaccine against Smallpox in Chronically HIV Type 1-Infected Individuals Undergoing HAART
- 1 June 2007
- journal article
- clinical trial
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 23 (6) , 782-793
Abstract
The fear of malevolent use of variola virus by terrorists has led to the implementation of a health care worker vaccination program and to the consideration of vaccination for the general public. However, due to concerns about side effects of the classical smallpox vaccine, especially for immunocompromised individuals, a safer vaccine is urgently needed. We characterized the immunogenicity of modified vaccinia virus Ankara (MVA), one of the more promising alternative smallpox vaccines, in a cohort of 10 chronically HIV-1-infected individuals undergoing highly active antiretroviral therapy (HAART). Nine subjects received smallpox vaccination as children while one subject was never vaccinated against smallpox. All the subjects had CD4 counts >400 cells/mm(3) and 8 out of 10 had undetectable viral loads. MVA was able to elicit humoral and cellular immune responses in the majority of individuals. Vaccinia-specific antibodies were mainly of the IgG class while T cells specific to vaccinia were predominantly CD8(+). The immune responses were maintained over 1 year. Similar vaccinia specific humoral immune responses were observed when our cohort of HIV-1-infected individuals was compared to smallpox-vaccinated healthy subjects. The observed immune responses suggest that the highly attenuated MVA could be used as a substitute vaccine against smallpox in chronically HIV-1-infected individuals undergoing HAART.Keywords
This publication has 37 references indexed in Scilit:
- Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell FunctionJournal of Virology, 2006
- Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+T-Cell EpitopesJournal of Virology, 2006
- Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag VaccineJournal of Virology, 2006
- Unintended Smallpox Vaccination of HIV-1--Infected Individuals in the United States MilitaryClinical Infectious Diseases, 2004
- Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia VirusClinical and Vaccine Immunology, 2004
- Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent ProteinJournal of Virology, 2003
- Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene ExpressionThe Journal of Infectious Diseases, 2003
- Smallpox Vaccination and Patients with Human Immunodeficiency Virus Infection or Acquired Immunodeficiency SyndromeClinical Infectious Diseases, 2003
- In Search of a Kinder, Gentler VaccineScience, 2002
- Developing New Smallpox VaccinesEmerging Infectious Diseases, 2001